BioSpace News Archive

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the year ended December 31, 2020 and provided a corporate strategic update.

SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, will report financial results for its fourth quarter and fiscal year 2020, ended December 31, 2020, after the market close on Thursday, March 25, 2021

111, Inc., a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, announced it has entered into a strategic cooperation agreement with BeiGene Co.,Ltd, a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide.

Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open-Label SHORELINE Study in Patients with MDD

Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower doses

PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance PRAX-944 Phase 2a high dose cohort topline data expected in mid-year 2021 Innovative collaboration with The Florey Institute expands pipeline via addition of 3 ASOs targeting rare epilepsies Cash Balance of $296.6M as of December 31, 2020 supports cash runway into 4Q22

Renowned Biotech Industry Innovator is Senior Partner at Flagship Pioneering, a member of Moderna Therapeutics’ Development Committee and former Chief Medical Officer of Merck

Seneca Biopharma, Inc. (Nasdaq: SNCA), today announced that leading independent proxy advisory firm Institutional Shareholder Services, Inc. (“ISS”) has recommended that Seneca stockholders vote in support of the proposed merger with Leading BioSciences, Inc.

Intermountain Healthcare, Choice Physicians Network, and Leading Healthcare Organizations rely on Harmonize’s AI-driven remote health solution driving 30% reduction in ER visits and hospitalizations

Valence Discovery (“Valence”), an emerging leader in AI-enabled drug design, today announced it has entered into a drug discovery agreement with Repare Therapeutics (“Repare”, Nasdaq: RPTX), a precision oncology company pioneering synthetic lethality to develop novel therapeutics for genetically-defined patient populations.